DSGN DESIGN THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, DESIGN THERAPEUTICS INC reported revenue of n/a, net income of −$20.2M and diluted EPS of −$0.32; for the fiscal year ended December 2025 revenue was $0.
DSGN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$79.5M, net income −$69.8M (margin n/a), EPS −$1.22
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$62.4M, net income −$49.6M (margin n/a), EPS −$0.88
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$78.2M, net income −$66.9M (margin n/a), EPS −$1.19
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$67.6M, net income −$63.3M (margin n/a), EPS −$1.14
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$35.8M, net income −$35.5M (margin n/a), EPS −$0.77
DSGN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$20.2M, EPS −$0.32
- Quarter ended Mar 31, 2026: revenue $0, net income −$17.6M, EPS −$0.29
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$16.0M, EPS −$0.27
- Quarter ended Sep 30, 2025: revenue n/a, net income −$17.0M, EPS −$0.30
- Quarter ended Jun 30, 2025: revenue n/a, net income −$19.1M, EPS −$0.34
- Quarter ended Mar 31, 2025: revenue $0, net income −$17.7M, EPS −$0.31
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$13.7M, EPS −$0.24
- Quarter ended Sep 30, 2024: revenue n/a, net income −$13.0M, EPS −$0.23
- Quarter ended Jun 30, 2024: revenue n/a, net income −$11.8M, EPS −$0.21
- Quarter ended Mar 31, 2024: revenue n/a, net income −$11.1M, EPS −$0.20
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$11.8M, EPS −$0.20
- Quarter ended Sep 30, 2023: revenue n/a, net income −$15.8M, EPS −$0.28
- Quarter ended Jun 30, 2023: revenue n/a, net income −$19.9M, EPS −$0.36
- Quarter ended Mar 31, 2023: revenue n/a, net income −$19.3M, EPS −$0.35
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$17.3M, EPS −$0.31
- Quarter ended Sep 30, 2022: revenue n/a, net income −$17.7M, EPS −$0.32
- Quarter ended Jun 30, 2022: revenue n/a, net income −$15.0M, EPS −$0.27
- Quarter ended Mar 31, 2022: revenue n/a, net income −$13.3M, EPS −$0.24
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$11.1M, EPS −$0.11
- Quarter ended Sep 30, 2021: revenue n/a, net income −$11.3M, EPS −$0.21
DSGN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$54.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$43.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$58.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$51.3M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$29.4M, share buybacks n/a
DSGN balance sheet
- Jun 30, 2026: cash $12.9M, total assets $215M, total liabilities $13.3M, shareholders' equity $202M
- Mar 31, 2026: cash $12.8M, total assets $230M, total liabilities $12.4M, shareholders' equity $218M
- Dec 31, 2025: cash $16.9M, total assets $226M, total liabilities $13.7M, shareholders' equity $213M
- Sep 30, 2025: cash $15.1M, total assets $212M, total liabilities $12.1M, shareholders' equity $200M
- Jun 30, 2025: cash $19.7M, total assets $223M, total liabilities $9.85M, shareholders' equity $213M
- Mar 31, 2025: cash $13.7M, total assets $237M, total liabilities $9.56M, shareholders' equity $228M
- Dec 31, 2024: cash $22.6M, total assets $252M, total liabilities $10.00M, shareholders' equity $242M
- Sep 30, 2024: cash $30.3M, total assets $262M, total liabilities $9.18M, shareholders' equity $252M
What is DSGN's revenue?
DESIGN THERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.
Is DSGN profitable?
No. DESIGN THERAPEUTICS INC lost $70.8M over the last four quarters.
What is DSGN's EPS?
Diluted earnings per share over the last four quarters were −$1.18; −$0.32 in the latest quarter.